Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crofelemer - Napo Pharmaceuticals

Next Previous
X
Search
Drug Profile

Crofelemer - Napo Pharmaceuticals

Alternative Names: CRO-HIV; CRO-IBS; CRO-ID; CRO-PED; Fulyzaq; Mytesi; Provir; SP 303; TRN-002- Napo Pharmaceuticals; Virend

Latest Information Update: 12 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shaman Pharmaceuticals
  • Developer Napo Pharmaceuticals; Salix Pharmaceuticals; Shaman Pharmaceuticals
  • Class Antidiarrhoeals; Biopolymers; Chromans; Flavonoids; Irritable bowel syndrome therapies; Phytotherapies; Small molecules
  • Mechanism of Action Chloride channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diarrhoea; Short bowel syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Diarrhoea
  • Phase II Irritable bowel syndrome; Short bowel syndrome
  • No development reported Inflammatory bowel diseases
  • Discontinued Herpes simplex virus infections; Influenza virus infections

Most Recent Events

  • 12 Dec 2024 Napo Pharmaceuticals plans a phase II trial for Microvillus Inclusion Disease (In Infants, In Children, In Adolescents) in USA, Italy and UAE in January 2025 (PO) (NCT06721871)
  • 25 Apr 2024 Jaguar plans clinical trial for Diarrhoea in 2022
  • 31 Dec 2023 Napo Pharmaceuticals has patents pending for Crofelemer for the treatment of short bowel syndrome and congenital diarrheal disorder in USA, Australia, Canada, China, Europe, Israel, Jordan, Japan, and the Gulf States

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top